APO Research
Talk to an analyst

APO RESEARCH · REPORT

Ulcerative Colitis Immunology Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Ulcerative Colitis Immunology Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

19 December 2025197 pages

Choose your research edition.

Industry ResearchUlcerative Colitis Immunology Drugs Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Ulcerative Colitis Immunology Drugs Industry Growth and Trends Forecast to 2032106 pages · $3,450 USDMarket StructureGlobal Ulcerative Colitis Immunology Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Ulcerative Colitis Immunology Drugs Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Ulcerative Colitis Immunology Drugs Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Ulcerative Colitis Immunology Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Ulcerative Colitis Immunology Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Ulcerative Colitis Immunology Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Ulcerative Colitis Immunology Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Ulcerative Colitis Immunology Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Ulcerative Colitis Immunology Drugs include Bristol-Myers Squibb Company, Celltrion Healthcare, Genentech USA, Inc., UCBCares, AbbVie Inc., AMGEN, Biogen, Pfizer Inc. and ROCHE, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Ulcerative Colitis Immunology Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Ulcerative Colitis Immunology Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Ulcerative Colitis Immunology Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Ulcerative Colitis Immunology Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Ulcerative Colitis Immunology Drugs Segment by Company

Bristol-Myers Squibb Company

Celltrion Healthcare

Genentech USA, Inc.

UCBCares

AbbVie Inc.

AMGEN

Biogen

Pfizer Inc.

ROCHE

Janssen Biotech, Inc.

Ulcerative Colitis Immunology Drugs Segment by Type

Infliximab

Etanercept

Tofacitinib

Certolizumab Pegol

Golimumab

Adalimumab

Abatacept

Others

Ulcerative Colitis Immunology Drugs Segment by Application

Crohn's Disease(CD)

Ulcerative Colitis(UC)

Rheumatoid Arthritis

Ankylosing Spondylitis(AS)

Psoriasis(Ps)

Ulcerative Colitis Immunology Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ulcerative Colitis Immunology Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Ulcerative Colitis Immunology Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ulcerative Colitis Immunology Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Ulcerative Colitis Immunology Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Ulcerative Colitis Immunology Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Ulcerative Colitis Immunology Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Ulcerative Colitis Immunology Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Ulcerative Colitis Immunology Drugs Industry Trends Table 2. Ulcerative Colitis Immunology Drugs Industry Drivers Table 3. Ulcerative Colitis Immunology Drugs Industry Opportunities and Challenges Table 4. Ulcerative Colitis Immunology Drugs Industry Restraints Table 5. Global Ulcerative Colitis Immunology Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Ulcerative Colitis Immunology Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Ulcerative Colitis Immunology Drugs Sales by Manufacturers (W Units) & (2021-2026) Table 8. Global Ulcerative Colitis Immunology Drugs Sales Market Share by Manufacturers Table 9. Global Ulcerative Colitis Immunology Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Ulcerative Colitis Immunology Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Ulcerative Colitis Immunology Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Ulcerative Colitis Immunology Drugs Manufacturers, Product Type & Application Table 13. Global Ulcerative Colitis Immunology Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Ulcerative Colitis Immunology Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Infliximab Table 17. Major Manufacturers of Etanercept Table 18. Major Manufacturers of Tofacitinib Table 19. Major Manufacturers of Certolizumab Pegol Table 20. Major Manufacturers of Golimumab Table 21. Major Manufacturers of Adalimumab Table 22. Major Manufacturers of Abatacept Table 23. Major Manufacturers of Others Table 24. Global Ulcerative Colitis Immunology Drugs Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 25. Global Ulcerative Colitis Immunology Drugs Sales by Type (2021-2026) & (W Units) Table 26. Global Ulcerative Colitis Immunology Drugs Sales by Type (2027-2032) & (W Units) Table 27. Global Ulcerative Colitis Immunology Drugs Sales Market Share by Type (2021-2026) Table 28. Global Ulcerative Colitis Immunology Drugs Sales Market Share by Type (2027-2032) Table 29. Global Ulcerative Colitis Immunology Drugs Revenue by Type 2021 VS 2025 VS 2032 (W Units) Table 30. Global Ulcerative Colitis Immunology Drugs Revenue by Type (2021-2026) & (W Units) Table 31. Global Ulcerative Colitis Immunology Drugs Revenue by Type (2027-2032) & (W Units) Table 32. Global Ulcerative Colitis Immunology Drugs Revenue Market Share by Type (2021-2026) Table 33. Global Ulcerative Colitis Immunology Drugs Revenue Market Share by Type (2027-2032) Table 34. Major Manufacturers of Crohn's Disease(CD) Table 35. Major Manufacturers of Ulcerative Colitis(UC) Table 36. Major Manufacturers of Rheumatoid Arthritis Table 37. Major Manufacturers of Ankylosing Spondylitis(AS) Table 38. Major Manufacturers of Psoriasis(Ps) Table 39. Global Ulcerative Colitis Immunology Drugs Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 40. Global Ulcerative Colitis Immunology Drugs Sales by Application (2021-2026) & (W Units) Table 41. Global Ulcerative Colitis Immunology Drugs Sales by Application (2027-2032) & (W Units) Table 42. Global Ulcerative Colitis Immunology Drugs Sales Market Share by Application (2021-2026) Table 43. Global Ulcerative Colitis Immunology Drugs Sales Market Share by Application (2027-2032) Table 44. Global Ulcerative Colitis Immunology Drugs Revenue by Application 2021 VS 2025 VS 2032 (W Units) Table 45. Global Ulcerative Colitis Immunology Drugs Revenue by Application (2021-2026) & (W Units) Table 46. Global Ulcerative Colitis Immunology Drugs Revenue by Application (2027-2032) & (W Units) Table 47. Global Ulcerative Colitis Immunology Drugs Revenue Market Share by Application (2021-2026) Table 48. Global Ulcerative Colitis Immunology Drugs Revenue Market Share by Application (2027-2032) Table 49. Global Ulcerative Colitis Immunology Drugs Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 50. Global Ulcerative Colitis Immunology Drugs Sales by Region (2021-2026) & (W Units) Table 51. Global Ulcerative Colitis Immunology Drugs Sales Market Share by Region (2021-2026) Table 52. Global Ulcerative Colitis Immunology Drugs Sales Forecasted by Region (2027-2032) & (W Units) Table 53. Global Ulcerative Colitis Immunology Drugs Sales Forecasted Market Share by Region (2027-2032) Table 54. North America Ulcerative Colitis Immunology Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 55. North America Ulcerative Colitis Immunology Drugs Sales by Country (2021-2026) & (W Units) Table 56. North America Ulcerative Colitis Immunology Drugs Sales by Country (2027-2032) & (W Units) Table 57. Europe Ulcerative Colitis Immunology Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 58. Europe Ulcerative Colitis Immunology Drugs Sales by Country (2021-2026) & (W Units) Table 59. Europe Ulcerative Colitis Immunology Drugs Sales by Country (2027-2032) & (W Units) Table 60. Asia Pacific Ulcerative Colitis Immunology Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 61. Asia Pacific Ulcerative Colitis Immunology Drugs Sales by Country (2021-2026) & (W Units) Table 62. Asia Pacific Ulcerative Colitis Immunology Drugs Sales by Country (2027-2032) & (W Units) Table 63. South America, Middle East and Africa Ulcerative Colitis Immunology Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 64. South America, Middle East and Africa Ulcerative Colitis Immunology Drugs Sales by Country (2021-2026) & (W Units) Table 65. South America, Middle East and Africa Ulcerative Colitis Immunology Drugs Sales by Country (2027-2032) & (W Units) Table 66. Global Ulcerative Colitis Immunology Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 67. Global Ulcerative Colitis Immunology Drugs Revenue by Region (2021-2026) & (US$ Million) Table 68. Global Ulcerative Colitis Immunology Drugs Revenue by Region (2027-2032) & (US$ Million) Table 69. Global Ulcerative Colitis Immunology Drugs Revenue Market Share by Region (2021-2026) Table 70. Global Ulcerative Colitis Immunology Drugs Revenue Market Share by Region (2027-2032) Table 71. Bristol-Myers Squibb Company Company Information Table 72. Bristol-Myers Squibb Company Business Overview Table 73. Bristol-Myers Squibb Company Ulcerative Colitis Immunology Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Bristol-Myers Squibb Company Ulcerative Colitis Immunology Drugs Product Portfolio Table 75. Bristol-Myers Squibb Company Recent Development Table 76. Celltrion Healthcare Company Information Table 77. Celltrion Healthcare Business Overview Table 78. Celltrion Healthcare Ulcerative Colitis Immunology Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Celltrion Healthcare Ulcerative Colitis Immunology Drugs Product Portfolio Table 80. Celltrion Healthcare Recent Development Table 81. Genentech USA, Inc. Company Information Table 82. Genentech USA, Inc. Business Overview Table 83. Genentech USA, Inc. Ulcerative Colitis Immunology Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Genentech USA, Inc. Ulcerative Colitis Immunology Drugs Product Portfolio Table 85. Genentech USA, Inc. Recent Development Table 86. UCBCares Company Information Table 87. UCBCares Business Overview Table 88. UCBCares Ulcerative Colitis Immunology Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. UCBCares Ulcerative Colitis Immunology Drugs Product Portfolio Table 90. UCBCares Recent Development Table 91. AbbVie Inc. Company Information Table 92. AbbVie Inc. Business Overview Table 93. AbbVie Inc. Ulcerative Colitis Immunology Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. AbbVie Inc. Ulcerative Colitis Immunology Drugs Product Portfolio Table 95. AbbVie Inc. Recent Development Table 96. AMGEN Company Information Table 97. AMGEN Business Overview Table 98. AMGEN Ulcerative Colitis Immunology Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. AMGEN Ulcerative Colitis Immunology Drugs Product Portfolio Table 100. AMGEN Recent Development Table 101. Biogen Company Information Table 102. Biogen Business Overview Table 103. Biogen Ulcerative Colitis Immunology Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. Biogen Ulcerative Colitis Immunology Drugs Product Portfolio Table 105. Biogen Recent Development Table 106. Pfizer Inc. Company Information Table 107. Pfizer Inc. Business Overview Table 108. Pfizer Inc. Ulcerative Colitis Immunology Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. Pfizer Inc. Ulcerative Colitis Immunology Drugs Product Portfolio Table 110. Pfizer Inc. Recent Development Table 111. ROCHE Company Information Table 112. ROCHE Business Overview Table 113. ROCHE Ulcerative Colitis Immunology Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. ROCHE Ulcerative Colitis Immunology Drugs Product Portfolio Table 115. ROCHE Recent Development Table 116. Janssen Biotech, Inc. Company Information Table 117. Janssen Biotech, Inc. Business Overview Table 118. Janssen Biotech, Inc. Ulcerative Colitis Immunology Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. Janssen Biotech, Inc. Ulcerative Colitis Immunology Drugs Product Portfolio Table 120. Janssen Biotech, Inc. Recent Development Table 121. Key Raw Materials Table 122. Raw Materials Key Suppliers Table 123. Ulcerative Colitis Immunology Drugs Distributors List Table 124. Ulcerative Colitis Immunology Drugs Customers List Table 125. Research Programs/Design for This Report Table 126. Authors List of This Report Table 127. Secondary Sources Table 128. Primary Sources List of Figures Figure 1. Ulcerative Colitis Immunology Drugs Product Image Figure 2. Global Ulcerative Colitis Immunology Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Ulcerative Colitis Immunology Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Ulcerative Colitis Immunology Drugs Sales (2021-2032) & (W Units) Figure 5. Global Ulcerative Colitis Immunology Drugs Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Ulcerative Colitis Immunology Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Infliximab Image Figure 9. Etanercept Image Figure 10. Tofacitinib Image Figure 11. Certolizumab Pegol Image Figure 12. Golimumab Image Figure 13. Adalimumab Image Figure 14. Abatacept Image Figure 15. Others Image Figure 16. Global Ulcerative Colitis Immunology Drugs Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 17. Global Ulcerative Colitis Immunology Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 18. Global Ulcerative Colitis Immunology Drugs Sales Market Share by Type (2021-2032) Figure 19. Global Ulcerative Colitis Immunology Drugs Revenue by Type (2021 VS 2025 VS 2032) & (W Units) Figure 20. Global Ulcerative Colitis Immunology Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Ulcerative Colitis Immunology Drugs Revenue Market Share by Type (2021-2032) Figure 22. Crohn's Disease(CD) Image Figure 23. Ulcerative Colitis(UC) Image Figure 24. Rheumatoid Arthritis Image Figure 25. Ankylosing Spondylitis(AS) Image Figure 26. Psoriasis(Ps) Image Figure 27. Global Ulcerative Colitis Immunology Drugs Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 28. Global Ulcerative Colitis Immunology Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 29. Global Ulcerative Colitis Immunology Drugs Sales Market Share by Application (2021-2032) Figure 30. Global Ulcerative Colitis Immunology Drugs Revenue by Application (2021 VS 2025 VS 2032) & (W Units) Figure 31. Global Ulcerative Colitis Immunology Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 32. Global Ulcerative Colitis Immunology Drugs Revenue Market Share by Application (2021-2032) Figure 33. North America Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 34. North America Ulcerative Colitis Immunology Drugs Sales Market Share by Country (2021-2032) Figure 35. U.S. Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 36. Canada Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 37. Mexico Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 38. Europe Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 39. Europe Ulcerative Colitis Immunology Drugs Sales Market Share by Country (2021-2032) Figure 40. Germany Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 41. France Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 42. U.K. Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 43. Italy Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 44. Netherlands Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 45. Asia Pacific Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 46. Asia Pacific Ulcerative Colitis Immunology Drugs Sales Market Share by Country (2021-2032) Figure 47. China Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 48. Japan Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 49. South Korea Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 50. Southeast Asia Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 51. India Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 52. Australia Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 53. South America, Middle East and Africa Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 54. South America, Middle East and Africa Ulcerative Colitis Immunology Drugs Sales Market Share by Country (2021-2032) Figure 55. Brazil Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 56. South Africa Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 57. Saudi Arabia Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 58. Turkey Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 59. Argentina Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 60. UAE Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 61. Egypt Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 62. Chile Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 63. Global Ulcerative Colitis Immunology Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Global Ulcerative Colitis Immunology Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 65. North America Ulcerative Colitis Immunology Drugs Revenue (2021-2032) & (US$ Million) Figure 66. North America Ulcerative Colitis Immunology Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Europe Ulcerative Colitis Immunology Drugs Revenue (2021-2032) & (US$ Million) Figure 68. Europe Ulcerative Colitis Immunology Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. Asia-Pacific Ulcerative Colitis Immunology Drugs Revenue (2021-2032) & (US$ Million) Figure 70. Asia-Pacific Ulcerative Colitis Immunology Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 71. South America, Middle East and Africa Ulcerative Colitis Immunology Drugs Revenue (2021-2032) & (US$ Million) Figure 72. South America, Middle East and Africa Ulcerative Colitis Immunology Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 73. Ulcerative Colitis Immunology Drugs Value Chain Figure 74. Manufacturing Cost Structure Figure 75. Ulcerative Colitis Immunology Drugs Production Mode & Process Figure 76. Direct Comparison with Distribution Share Figure 77. Distributors Profiles Figure 78. Years Considered Figure 79. Research Process Figure 80. Key Executives Interviewed

Scope & coverage.

Types
  • Infliximab
  • Etanercept
  • Tofacitinib
  • Certolizumab Pegol
  • Golimumab
  • Adalimumab
  • Abatacept
  • Others
Applications
  • Crohn's Disease(CD)
  • Ulcerative Colitis(UC)
  • Rheumatoid Arthritis
  • Ankylosing Spondylitis(AS)
  • Psoriasis(Ps)
Companies covered
  • Bristol-Myers Squibb Company
  • Celltrion Healthcare
  • Genentech USA, Inc.
  • UCBCares
  • AbbVie Inc.
  • AMGEN
  • Biogen
  • Pfizer Inc.
  • ROCHE
  • Janssen Biotech, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Ulcerative Colitis Immunology Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Ulcerative Colitis Immunology Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Ulcerative Colitis Immunology Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Ulcerative Colitis Immunology Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Ulcerative Colitis Immunology Drugs Market Dynamics
  1. 2.1 Ulcerative Colitis Immunology Drugs Industry Trends
  2. 2.2 Ulcerative Colitis Immunology Drugs Industry Drivers
  3. 2.3 Ulcerative Colitis Immunology Drugs Industry Opportunities and Challenges
  4. 2.4 Ulcerative Colitis Immunology Drugs Industry Restraints
3 Ulcerative Colitis Immunology Drugs Market by Manufacturers
  1. 3.1 Global Ulcerative Colitis Immunology Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Ulcerative Colitis Immunology Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Ulcerative Colitis Immunology Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Ulcerative Colitis Immunology Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Ulcerative Colitis Immunology Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Ulcerative Colitis Immunology Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Ulcerative Colitis Immunology Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Ulcerative Colitis Immunology Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Ulcerative Colitis Immunology Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Ulcerative Colitis Immunology Drugs Tier 1, Tier 2, and Tier 3
4 Ulcerative Colitis Immunology Drugs Market by Type
  1. 4.1 Ulcerative Colitis Immunology Drugs Type Introduction
  2. 4.1.1 Infliximab
  3. 4.1.2 Etanercept
  4. 4.1.3 Tofacitinib
  5. 4.1.4 Certolizumab Pegol
  6. 4.1.5 Golimumab
  7. 4.1.6 Adalimumab
  8. 4.1.7 Abatacept
  9. 4.1.8 Others
  10. 4.2 Global Ulcerative Colitis Immunology Drugs Sales by Type
  11. 4.2.1 Global Ulcerative Colitis Immunology Drugs Sales by Type (2021 VS 2025 VS 2032)
  12. 4.2.2 Global Ulcerative Colitis Immunology Drugs Sales by Type (2021-2032)
  13. 4.2.3 Global Ulcerative Colitis Immunology Drugs Sales Market Share by Type (2021-2032)
  14. 4.3 Global Ulcerative Colitis Immunology Drugs Revenue by Type
  15. 4.3.1 Global Ulcerative Colitis Immunology Drugs Revenue by Type (2021 VS 2025 VS 2032)
  16. 4.3.2 Global Ulcerative Colitis Immunology Drugs Revenue by Type (2021-2032)
  17. 4.3.3 Global Ulcerative Colitis Immunology Drugs Revenue Market Share by Type (2021-2032)
5 Ulcerative Colitis Immunology Drugs Market by Application
  1. 5.1 Ulcerative Colitis Immunology Drugs Application Introduction
  2. 5.1.1 Crohn's Disease(CD)
  3. 5.1.2 Ulcerative Colitis(UC)
  4. 5.1.3 Rheumatoid Arthritis
  5. 5.1.4 Ankylosing Spondylitis(AS)
  6. 5.1.5 Psoriasis(Ps)
  7. 5.2 Global Ulcerative Colitis Immunology Drugs Sales by Application
  8. 5.2.1 Global Ulcerative Colitis Immunology Drugs Sales by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Ulcerative Colitis Immunology Drugs Sales by Application (2021-2032)
  10. 5.2.3 Global Ulcerative Colitis Immunology Drugs Sales Market Share by Application (2021-2032)
  11. 5.3 Global Ulcerative Colitis Immunology Drugs Revenue by Application
  12. 5.3.1 Global Ulcerative Colitis Immunology Drugs Revenue by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Ulcerative Colitis Immunology Drugs Revenue by Application (2021-2032)
  14. 5.3.3 Global Ulcerative Colitis Immunology Drugs Revenue Market Share by Application (2021-2032)
6 Global Ulcerative Colitis Immunology Drugs Sales by Region
  1. 6.1 Global Ulcerative Colitis Immunology Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Ulcerative Colitis Immunology Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Ulcerative Colitis Immunology Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Ulcerative Colitis Immunology Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Ulcerative Colitis Immunology Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Ulcerative Colitis Immunology Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Ulcerative Colitis Immunology Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Ulcerative Colitis Immunology Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Ulcerative Colitis Immunology Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Ulcerative Colitis Immunology Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Ulcerative Colitis Immunology Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Ulcerative Colitis Immunology Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Ulcerative Colitis Immunology Drugs Revenue by Region
  1. 7.1 Global Ulcerative Colitis Immunology Drugs Revenue by Region
  2. 7.1.1 Global Ulcerative Colitis Immunology Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Ulcerative Colitis Immunology Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Ulcerative Colitis Immunology Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Ulcerative Colitis Immunology Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Ulcerative Colitis Immunology Drugs Revenue (2021-2032)
  8. 7.2.2 North America Ulcerative Colitis Immunology Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Ulcerative Colitis Immunology Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Ulcerative Colitis Immunology Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Ulcerative Colitis Immunology Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Ulcerative Colitis Immunology Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Ulcerative Colitis Immunology Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Ulcerative Colitis Immunology Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Bristol-Myers Squibb Company
  2. 8.1.1 Bristol-Myers Squibb Company Company Information
  3. 8.1.2 Bristol-Myers Squibb Company Business Overview
  4. 8.1.3 Bristol-Myers Squibb Company Ulcerative Colitis Immunology Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Bristol-Myers Squibb Company Ulcerative Colitis Immunology Drugs Product Portfolio
  6. 8.1.5 Bristol-Myers Squibb Company Recent Developments
  7. 8.2 Celltrion Healthcare
  8. 8.2.1 Celltrion Healthcare Company Information
  9. 8.2.2 Celltrion Healthcare Business Overview
  10. 8.2.3 Celltrion Healthcare Ulcerative Colitis Immunology Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Celltrion Healthcare Ulcerative Colitis Immunology Drugs Product Portfolio
  12. 8.2.5 Celltrion Healthcare Recent Developments
  13. 8.3 Genentech USA, Inc.
  14. 8.3.1 Genentech USA, Inc. Company Information
  15. 8.3.2 Genentech USA, Inc. Business Overview
  16. 8.3.3 Genentech USA, Inc. Ulcerative Colitis Immunology Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Genentech USA, Inc. Ulcerative Colitis Immunology Drugs Product Portfolio
  18. 8.3.5 Genentech USA, Inc. Recent Developments
  19. 8.4 UCBCares
  20. 8.4.1 UCBCares Company Information
  21. 8.4.2 UCBCares Business Overview
  22. 8.4.3 UCBCares Ulcerative Colitis Immunology Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 UCBCares Ulcerative Colitis Immunology Drugs Product Portfolio
  24. 8.4.5 UCBCares Recent Developments
  25. 8.5 AbbVie Inc.
  26. 8.5.1 AbbVie Inc. Company Information
  27. 8.5.2 AbbVie Inc. Business Overview
  28. 8.5.3 AbbVie Inc. Ulcerative Colitis Immunology Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 AbbVie Inc. Ulcerative Colitis Immunology Drugs Product Portfolio
  30. 8.5.5 AbbVie Inc. Recent Developments
  31. 8.6 AMGEN
  32. 8.6.1 AMGEN Company Information
  33. 8.6.2 AMGEN Business Overview
  34. 8.6.3 AMGEN Ulcerative Colitis Immunology Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 AMGEN Ulcerative Colitis Immunology Drugs Product Portfolio
  36. 8.6.5 AMGEN Recent Developments
  37. 8.7 Biogen
  38. 8.7.1 Biogen Company Information
  39. 8.7.2 Biogen Business Overview
  40. 8.7.3 Biogen Ulcerative Colitis Immunology Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Biogen Ulcerative Colitis Immunology Drugs Product Portfolio
  42. 8.7.5 Biogen Recent Developments
  43. 8.8 Pfizer Inc.
  44. 8.8.1 Pfizer Inc. Company Information
  45. 8.8.2 Pfizer Inc. Business Overview
  46. 8.8.3 Pfizer Inc. Ulcerative Colitis Immunology Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Pfizer Inc. Ulcerative Colitis Immunology Drugs Product Portfolio
  48. 8.8.5 Pfizer Inc. Recent Developments
  49. 8.9 ROCHE
  50. 8.9.1 ROCHE Company Information
  51. 8.9.2 ROCHE Business Overview
  52. 8.9.3 ROCHE Ulcerative Colitis Immunology Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 ROCHE Ulcerative Colitis Immunology Drugs Product Portfolio
  54. 8.9.5 ROCHE Recent Developments
  55. 8.10 Janssen Biotech, Inc.
  56. 8.10.1 Janssen Biotech, Inc. Company Information
  57. 8.10.2 Janssen Biotech, Inc. Business Overview
  58. 8.10.3 Janssen Biotech, Inc. Ulcerative Colitis Immunology Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Janssen Biotech, Inc. Ulcerative Colitis Immunology Drugs Product Portfolio
  60. 8.10.5 Janssen Biotech, Inc. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Ulcerative Colitis Immunology Drugs Value Chain Analysis
  2. 9.1.1 Ulcerative Colitis Immunology Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Ulcerative Colitis Immunology Drugs Production Mode & Process
  6. 9.2 Ulcerative Colitis Immunology Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Ulcerative Colitis Immunology Drugs Distributors
  9. 9.2.3 Ulcerative Colitis Immunology Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst